ONDCP Director Dr. Rahul Gupta Visits St. Paul and Minneapolis to Meet with Leaders on the Front Lines of the Overdose Epidemic May 08, 2023 • Press Releases
NEJM Publishes ONDCP Op-ed on the Medical and Public Health Imperatives Surrounding Xylazine, which Dr. Gupta Designated as an Emerging Drug Threat to the Nation April 26, 2023 • Press Releases
In Philadelphia, ONDCP Director Meets with Leaders on the Front Lines of Fentanyl and Xylazine Crisis April 24, 2023 • Press Releases
United States Elected to the Presidency of the American Sports Council, Will Serve on the World Anti-Doping Agency’s Executive Committee April 19, 2023 • Press Releases
ONDCP Director Statement on New CMS Guidance to Increase Access to Addiction Treatment in Carceral Facilities April 17, 2023 • Press Releases
Dr. Rahul Gupta Releases Statement on DOJ’s New Drug Enforcement Actions April 14, 2023 • Press Releases
Biden-Harris Administration Designates Fentanyl Combined with Xylazine as an Emerging Threat to the United States April 12, 2023 • Press Releases
Biden-Harris Administration Launches Campaign to Raise Awareness About the Dangers of Fentanyl and the Life-Saving Effects of Naloxone in Partnership with the Ad Council April 06, 2023 • Press Releases
Dr. Gupta Applauds FDA Announcement to Make First Naloxone Product Available Over-the-Counter March 29, 2023 • Press Releases
RELEASE: Dr. Rahul Gupta Releases Statement on CDC’s New Overdose Death Data March 16, 2023 • Press Releases
